Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04449874
Title A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Genentech, Inc.
Indications

lung non-small cell carcinoma

colorectal cancer

Advanced Solid Tumor

Therapies

Atezolizumab + GDC-6036

Bevacizumab + GDC-6036

Cetuximab + GDC-6036

Erlotinib + GDC-6036

GDC-6036

Age Groups: adult
Covered Countries USA | ITA | ESP | CAN | BEL


No variant requirements are available.